← Eichor
Condition: Adebrelimab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Adebrelimab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of T
Phase 2 · 1 location(s) · Shengjing Hospital · NCT06165900Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for
Phase 2 · 1 location(s) · Ningbo Medical Center Lihuili Hospital · NCT07542002Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
Phase N/A · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06102772A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06415669Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06298968A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally
Phase 2/Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07454720Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06510660GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
Phase 2 · 12 location(s) · Sun Yat-sen University · NCT06455410The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-re
Phase 2 · 1 location(s) · Sir Run Run Shaw Hospital · NCT06266832Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
Phase 2 · 1 location(s) · Mian XI · NCT06261125A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage
Phase 2 · 2 location(s) · Henan Cancer Hospital · NCT07559786Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebreli
Phase 2 · 1 location(s) · The Fourth Affiliated Hospital of Zhejiang University School · NCT06282445Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ
Phase 2 · 1 location(s) · Jiangsu Cancer Institute & Hospital · NCT06985602Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Phase 2 · 1 location(s) · Beijing Chest Hospital, Capital Medical University · NCT06467617Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
Phase 2 · 1 location(s) · Qilu Hospital of Shandong University · NCT06454578Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocell
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT05970666Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
Phase 2 · 1 location(s) · Fudan University · NCT07638852SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
Phase 2 · 1 location(s) · Shengjing Hospital · NCT06340230A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concur
Phase 3 · 1 location(s) · Shanghai Shengdi Pharmaceutical Co., Ltd · NCT07168200Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune
Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06339619Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT06418594HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treat
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07131514Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Pos
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06885814Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in th
Phase 2 · 1 location(s) · Fudan University · NCT06943235Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Ca
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06562920A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cance
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT06474468Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
Phase 2 · 2 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07718490Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06433609Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05753826Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
Phase 2 · 1 location(s) · Tang-Du Hospital · NCT06663059
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.